Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis
Authors: Lawler, Patrick R;Liu, Vincent X;Fohner, Alison E;Goodman, Shaun G;et al.
Crit Care Explor. 2023 Nov;5(11):e0997. Epub 2023-11-08.
PubMed abstract
Assessing clinical heterogeneity in sepsis through treatment patterns and machine learning
Authors: Fohner AE; Greene JD; Lawson BL; Chen JH; Kipnis P; Escobar GJ; Liu VX
J Am Med Inform Assoc. 2019 12 01;26(12):1466-1477.
PubMed abstract
Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system
Authors: Fohner AE; Ranatunga DK; Thai KK; Lawson BL; Risch N; Oni-Orisan A; Jelalian AT; Rettie AE; Liu VX; Schaefer CA
Pharmacogenet Genomics. 2019 10;29(8):192-199.
PubMed abstract
Carnitine palmitoyltransferase 1A P479L and infant death: policy implications of emerging data.
Authors: Fohner AE; Garrison NA; ,; Austin MA; Burke W;
Genet Med. 2017 Aug;19(8):851-857. doi: 10.1038/gim.2016.202. Epub 2017 Jan 26.
PubMed abstract
Genetics, Diet, and Season Are Associated with Serum 25-Hydroxycholecalciferol Concentration in a Yup’ik Study Population from Southwestern Alaska.
Authors: Fohner AE; Wang Z; Yracheta J; O'Brien DM; Hopkins SE; Black J; Philip J; Wiener HW; Tiwari HK; Stapleton PL; Tsai JM; Thornton TA; Boyer BB; Thummel KE
J Nutr. 2016 Feb;146(2):318-25. doi: 10.3945/jn.115.223388. Epub 2015 Dec 9.
PubMed abstract
Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX.
Authors: Fohner AE; Robinson R; Yracheta J; Dillard DA; Schilling B; Khan B; Hopkins S; Boyer B; Black J; Wiener H; Tiwari HK; Gordon A; Nickerson D; Tsai JM; Farin FM; Thornton TA; Rettie AE; Thummel KE
Pharmacogenet Genomics. 2015 Jul;25(7):343-353. doi: 10.1097/FPC.0000000000000143.
PubMed abstract